FrancophonIA/ELRC3.0 huggingface dataset:
English: The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy.
Croatian: U ispitivanju CLARITY sudjelovao je 3491 bolesnik primljen u roku od 12 sati od početka infarkta miokarda uz elevaciju ST segmenta uz planiranu trombolitičku terapiju.
English: Mylan bvba/sprl /Tel: + 32 (0)2 658 61 00 (Belgique/Belgien)
Croatian: Luxembourg/Luxemburg Mylan bvba/sprl Tel: + 32 (0)2 658 61 00 (Belgique/Belgien)
English: ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics.
Croatian: Akutni infarkt miokarda s elevacijom ST segmenta: klopidogrel se primjenjuje u dozama od 75 mg jednom dnevno uz početnu udarnu dozu od 300 mg u kombinaciji s acetilsalicilnom kiselinom i uz trombolitike ili bez njih.
English: Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Croatian: U odraslih bolesnika s atrijskom fibrilacijom i najmanje jednim faktorom rizika za vaskularne događaje koji se ne mogu liječiti antagonistima vitamina K te s malim rizikom od krvarenja indiciran je klopidogrel u kombinaciji s acetilsalicilnom kiselinom radi prevencije aterotromboze i tromboembolije, uključujući moždani udar.
English: In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Croatian: Konkretno, podaci dobiveni tijekom post-hoc analize 2172 bolesnika (17% ukupne populacije ispitivanja CURE) podvrgnutih ugradnji stenta (Stent-CURE) pokazali su da je klopidogrel u odnosu na placebo znatno smanjio relativni rizik od prve primarne krajnje točke (smrti uzrokovane kardiovaskularnim događajem, infarkta miokarda, moždanog udara) za 26,2% te za 23,9% od druge primarne krajnje točke (smrti uzrokovane kardiovaskularnim događajem, infarkta miokarda, moždanog udara ili refraktorne ishemije).
English: Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
Croatian: U petnaest posto (15,0%) bolesnika iz skupine koja je primala klopidogrel te 21,7% bolesnika iz skupine koja je primala placebo došlo je do krajnje točke, što predstavlja apsolutno smanjenje od 6,7% te smanjenje izgleda od 36% uzrokovano klopidogrelom (95-postotni interval pouzdanosti: 24, 47%; p < 0,001), uglavnom povezano sa smanjenjem broja okluzija arterija odgovornih za razvoj infarkta.
English: Rare side effect (may affect up to 1 in 1000 people): Vertigo, enlarged breasts in males.
Croatian: Rijetke nuspojave (javljaju se kod manje od 1 od 1000 korisnika): vrtoglavica, povećane grudi kod muškaraca.
English: Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
Croatian: bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvane lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
English: Calendar Blister of OPA/Al/PVC-Al containing 7, 14, 28, 56, 84 film-coated tablets in the box.
Croatian: Blister od OPA/Al/PVC-Al koji sadrži 7, 14, 28, 56 i 84 filmom obloženih tableta u kutiji.
English: Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
Croatian: To pokazuje da se koristi zabilježene u skupini koja je primala klopidogrel + ASA nisu povećavale nakon tri mjeseca liječenja, a opasnost od krvarenja ostala je ista (vidjeti dio 4.4).
English: Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section
Croatian: U bolesnika je potrebno provjeriti anamnezu preosjetljivosti na tienopiridine (kao što su klopidogrel, tiklopidin, prasugrel) jer je zabilježena križna reaktivnost među tienopiridinima (vidjeti dio 4.8).
English: In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Croatian: U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, BPA) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI: 8,9 do 36,2), a manja korist (ne značajno različita od učinka ASK) uočena je u bolesnika s moždanim udarom (RRR = 7,3%; CI: -5,7 do 18,7 [p = 0,258]).
English: If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Mylan.
Croatian: Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja lijeka Clopidogrel Mylan.
English: The concomitant administration of medicinal products associated with bleeding risk should be undertaken with caution (see section 4.4).
Croatian: Potreban je oprez pri istodobnoj primjeni lijekova povezanih s rizikom od krvarenja (vidjeti dio 4.4).
English: The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment.
Croatian: U ispitivanju ACTIVE-A sudjelovali su bolesnici koji nisu mogli ili nisu željeli primati terapiju antagonistima vitamina K.
English: Acute liver failure, hepatitis, abnormal liver function test
Croatian: Hepatobilijarni poremećaji akutno zatajenje jetre, hepatitis, abnormalni nalazi jetrene funkcije
English: If you are breast-feeding or planning to breast-feed, talk to your doctor before taking this medicine.
Croatian: Ako dojite ili planirate dojiti, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
English: While you are taking Clopidogrel Mylan:
Croatian: Dok uzimate Clopidogrel Mylan:
English: Clopidogrel Mylan 75 mg film-coated tablets clopidogrel
Croatian: Clopidogrel Mylan 75 mg filmom obložene tablete klopidogrel
English: In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =
Croatian: U bolesnika koji su u studiju uključeni samo zbog nedavnog infarkta miokarda, klopidogrel je bio brojčano slabiji, ali se statistički nije razlikovao od ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p = 0,639]).
English: Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Croatian: Bolesnici su slučajnim odabirom raspoređeni u skupinu koja prima klopidogrel (udarnu dozu od 300 mg te dnevne doze od 75 mg, N = 6,259) ili placebo (N = 6,303), a oboje u kombinaciji s ASA-om (75 - 325 mg jednom na dan) i drugim standardnim terapijama.
English: As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
Croatian: Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 nije preporučena (za popis inhibitora CYP2C19 vidjeti dio 4.5, također vidjeti dio 5.2).
English: Boxes of 7, 14, 28, 56, 84 film-coated tablets in calendar blisters are available.
Croatian: Dostupne su kutije sa 7, 14, 28, 56, 84 filmom obloženih tableta u blisterima s kalendarom.
English: Tabulated list of adverse reactions
Croatian: Tabelarni popis nuspojava
English: The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Croatian: Broj bolesnika u kojih je došlo do primarne krajnje točke ispitivanja [smrt uzrokovana kardiovaskularnim događajem, infarkt miokarda ili moždani udar] u grupi liječenoj klopidogrelom bio je 582 (9,3%), a u grupi liječenoj placebom 719 (11,4%), uz 20-postotno smanjenje relativnog rizika (95-postotni interval pouzdanosti 10% - 28%; p = 0,00009) u skupini liječenoj klopidogrelom (17postotno smanjenje relativnog rizika prilikom konzervativnog liječenja bolesnika, 29-postotno smanjenje u bolesnika podvrgnutih perkutanoj transluminalnoj koronarnoj angioplastici s ugradnjom stenta ili bez njega te 10-postotno u bolesnika podvrgnutih ugradnji premosnice na koronarnoj arteriji).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/559/001-016
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/559/001-016
English: Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
Croatian: Bolesnici su tijekom 28 dana ili do otpuštanja iz bolnice primali klopidogrel (75 mg na dan, n = 22.961) ili placebo (n = 22.891) u kombinaciji s ASA-om (162 mg/dan).
English: SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution.
Croatian: Selektivni inhibitori ponovne pohrane serotonina (SSRI): budući da SSRI utječu na aktivaciju trombocita i povećavaju rizik od krvarenja, kod istodobne upotrebe SSRI i klopidogrela potreban je oprez.
English: There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Croatian: U stopama krvarenja sa smrtnim posljedicama (1,1% u skupini koja je primala klopidogrel + ASA odnosno 0,7% u skupini koja je primala placebo +ASA) i hemoragijskog moždanog udara (0,8% odnosno 0,6%) nije bilo statistički bitne razlike među grupama.
English: As a precaution, concomitant use of omeprazole or esomeprazole should be discouraged (see section 4.4).
Croatian: Kao mjera opreza, ne preporučuje se se istodobna primjena s omeprazolom i esomeprozolom (vidjeti dio 4.4).
English: Musculoskeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva mišićnokoštano krvarenje (hemartroza), artritis, artralgija, mijalgija
English: Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Croatian: Bolesnici su primali klopidogrel (udarnu dozu od 300 mg, a zatim 75 mg na dan, n = 1752) ili placebo (n = 1739) u kombinaciji s ASA-om (udarnu dozu od 150 do 325 mg, a zatim 75 do 162 mg na dan), fibrinolitički agens i, ako je bilo potrebno, heparin.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel Mylan 75 mg film-coated tablets
Croatian: NAZIV LIJEKA Clopidogrel Mylan 75 mg filmom obložene tablete
English: Do not take Clopidogrel Mylan
Croatian: Nemojte uzimati Clopidogrel Mylan:
English: Marketing Authorisation Holder Mylan S.A.S, 117 allée des Parcs, 69 800 Saint Priest, France
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Mylan S.A.S, 117 allee des Parcs, 69 800 Saint Priest, Francuska
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Mylan S.A.S, 117 allée des Parcs, 69 800 Saint Priest, France
Croatian: 11. IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Mylan S.A.S, 117 allee des Parcs, 69 800 Saint Priest, Francuska
English: In ACTIVE A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%).
Croatian: Tijekom kliničkog ispitivanja ACTIVE-A u skupini koja je primala klopidogrel + ASA zabilježena je veća stopa jakog krvarenja nego u skupini koja je primala placebo + ASA (6,7% u odnosu na 4,3%).
English: Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn.
Croatian: Česte nuspojave (javljaju se kod manje od 1 od 10 korisnika): proljev, bol u trbuhu, loša probava ili žgaravica.
English: How to take Clopidogrel Mylan
Croatian: Kako uzimati Clopidogrel Mylan
English: There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Croatian: + ASA bila je veća pojavnost intrakranijalnog krvarenja nego u skupini koja je primala placebo + ASA (1,4% u odnosu na 0,8%).
English: Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Croatian: Da bi bili uključeni u ispitivanje, bolesnici su morali imati promjene EKG-a sukladne s novom ishemijom ili razine srčanih enzima ili troponima
English: Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy.
Croatian: Ne preporučuje se uzimanje ovog lijeka tijekom trudnoće.
English: Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000
Croatian: Koloidni bezvodni silicijev dioksidkrospovidon (tip A) makrogol 6000 ricinusovo ulje, hidrogenirano
English: In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
Croatian: Sigurnost i djelotvornost klopidogrela u bolesnika s infarktom miokarda uz akutnu elevaciju ST segmenta procijenjene su tijekom dva randomizirana dvostruko slijepa ispitivanja kontrolirana placebom: CLARITY i COMMIT.
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Croatian: Broj bolesnika u kojih je došlo do primarne krajnje točke (smrti uzrokovane kardiovaskularnim događajem, moždanog udara ili refraktorne ishemije) bio je 1035 (16,5%) u skupini liječenoj klopidogrelom te 1187 (18,8%) u skupini liječenoj placebom, uz 14-postotno smanjenje relativnog rizika (95-postotni interval pouzdanosti od 6% - 21%, p = 0,0005) u skupini liječenoj klopidogrelom.
English: The other ingredients are: Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000, hydrogenated castor oil (see section 2 ‘Clopidogrel Mylan contains hydrogenated castor oil') Film-coating: polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
Croatian: Jezgra tablete: mikrokristalinična celuloza, silicijev dioksid, koloidni, bezvodni, krospovidon (tip A), makrogol 6000, hidrogenizirano ricinusovo ulje (vidjeti dio 2 "Clopidogrel Mylan sadrži hidrogenizirano ricinusovo ulje")
English: Τηλ: + 357 99403969
Croatian: Pharmaceutical Trading Co Ltd Τηλ: + 357 99403969
English: • if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body).
Croatian: • Ako postoji opasnost od krvarenja poput medicinskih stanja kod kojih postoji opasnost od unutrašnjeg krvarenja (kao što je želučani čir), poremećaja krvi zbog čega ste skloni unutrašnjim krvarenjima (krvarenje u tkivima, organima ili zglobovima), nedavne teške ozljede, nedavnog kirurškog zahvata (uključujući stomatološke zahvate), planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
English: The number of patients who reached the primary endpoint (time to first occurrence of stroke, MI, non-CNS systemic embolism or vascular death) was 832 (22.1%) in the group treated with clopidogrel + ASA and 924 (24.4%) in the placebo + ASA group (relative risk reduction of 11.1%; 95% CI of 2.4% to 19.1%; p=0.013), primarily due to a large reduction in the incidence of strokes.
Croatian: Broj bolesnika u kojih je došlo do primarne krajnje točke (vrijeme do prve pojave moždanog udara, infarkt miokarda, sistemska embolija koja nije vezana uz središnji živčani sustav, smrt uzrokovana vaskularnim događajem) bio je 832 (22,1%) u skupini liječenoj klopidogrelom + ASA-om te 924 (24,4%) u skupini liječenoj placebom + ASA-om (smanjenje relativnog rizika od 11,1%; 95-postotni interval pouzdanosti od 2,4% do 19,1%; p = 0,013), prvenstveno zbog velikog smanjenje pojave moždanog udara.
English: In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Croatian: U analizi ITT (engl. 'intention to treat') zabilježeno je 939 slučajeva u skupini koja je primala klopidogrel, a 1020 u skupini koja je primala ASK (realtivno smanjenje rizika, RRR - engl. relative risk reduction = 8,7% [95% CI: 0,2 do 16,4]; p = 0,045) što, odgovara broju od dodatnih 10 bolesnika kojima je spriječen novi ishemijski događaj, na svakih 1.000 bolesnika liječenih 2 godine [CI: 0 do 20]. Analiza ukupne smrtnosti, sekundarnog ishoda studije, nije pokazala značajnu razliku između klopidogrela (5,8%) i ASK (6,0%).
English: You have an irregular heartbeat, a condition called ‘atrial fibrillation', and you cannot take medicines known as ‘oral anticoagulants' (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing.
Croatian: Liječnik vam je trebao propisati i acetilsalicilnu kiselinu (tvar koja se nalazi u brojnim lijekovima za ublažavanje bolova i snižavanje tjelesne temperature te za sprječavanje stvaranja krvnih ugrušaka) imate nepravilne otkucaje srca, što se naziva "atrijskom fibrilacijom", i ne možete uzimati lijekove koji se nazivaju "oralnim antikoagulansima" (antagoniste vitamina K), koji sprječavaju stvaranje novih ugrušaka te rast postojećih ugrušaka.
English: If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Mylan in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Croatian: Ako osjećate jake bolove u prsima (zbog nestabilne angine ili srčanog udara), može vam biti propisan Clopidogrel Mylan u kombinaciji s acetilsalicilnom kiselinom supstancom koja je prisutna u brojnim lijekovima za ublažavanje bolesti i snižavanje tjelesne temperature.Povremeno uzimanje acetilsalicilatne kiseline (ne više od 1.000 mg u 24 sata), općenito ne izaziva probleme, ali o produljenom uzimanju u drugim okolnostima morate razgovarati s liječnikom.
English: 30x1 film-coated tablets EU/1/09/559/010
Croatian: 30x1 filmom obloženih tableta EU/1/09/559/010
English: 50x1 film-coated tablets EU/1/09/559/011
Croatian: 50x1 filmom obloženih tableta EU/1/09/559/011
English: Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.
Croatian: Manje česte nuspojave (javljaju se kod manje od 1 od 100 korisnika): glavobolja, ulkus želuca, povraćanje, mučnina, zatvor, povećano stvaranje plinova u želucu ili crijevima, osip, svrbež, omaglica, osjećaj trnaca i utrnulosti.
English: CALENDAR BLISTER (boxes of 7, 14, 28, 56 or 84 tablets)
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER S KALENDAROM (kutije sa 7, 14, 28, 56 ili 84 tablete)
English: heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Croatian: Kao i u slučaju drugih antitrombocitnih lijekova, klopidogrel s oprezom treba davati bolesnicima koji su izloženi povećanom riziku od krvarenja zbog povrede, kirurških zahvata ili drugih patoloških stanja te bolesnicima koji se liječe s ASK, heparinom, inhibitorima glikoproteina IIb/IIIa ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući Cox-2 inhibitore ili selektivne inhibitore ponovne pohrane serotonina (SSRI) ili druge lijekove povezane s rizikom od krvarenja kao što je pentoksifilin (vidjeti dio 4.5).
English: As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
Croatian: Kao mjera opreza, ne preporučuje se istodobna primjena klopidogrela i lijekova koji su jaki ili umjereni inhibitori CYP2C19 nije preporučena (vidjeti dio 4.4 i 5.2).
English: If you forget to take Clopidogrel Mylan
Croatian: Ako ste zaboravili uzeti Clopidogrel Mylan:
English: How to store Clopidogrel Mylan
Croatian: Kako čuvati Clopidogrel Mylan
English: If you stop taking Clopidogrel Mylan
Croatian: Ako prestanete uzimati Clopidogrel Mylan:
English: Epistaxis
Croatian: Κύπρος
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Croatian: Poremećaji krvi i limfnog sustava trombocitopenija, leukopenija, eozinofilija neutropenija, uključujući tešku neutropeniju trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), aplastična anemija, panciopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
English: Clopidogrel is indicated in:
Croatian: Sekundarna prevencija aterotrombotičkih događaja Klopidogrel je indiciran u:
English: What Clopidogrel Mylan looks like and contents of the pack The film-coated tablets are pink, round and biconvex.
Croatian: Filmom obložene tablete su ružičaste, okrugle i bikonveksne.
English: 84 film-coated tablets: EU/1/09/559/007
Croatian: 84 filmom obloženih tableta: EU/1/09/559/007
English: 90 film-coated tablets: EU/1/09/559/008
Croatian: 90 filmom obloženih tableta: EU/1/09/559/008